-

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News:

VALERIO THERAPEUTICS (Paris:ALVIO):

 Name of Director

Other offices and functions

 

Julien MIARA

Chief Executive Officer and Director

 

  • Managing Director at Invus
  • Director of Sensorion
  • Director of Versity

 

Jacques MALLET

Director and Chairman of the Board

 

  • Chairman of Gamma-X Corporate Advisory
  • Director of Technoflex
  • Director of the Fournier Majoie Foundation

 

FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA

Director

 

  • Manager of SARL Financière de la Montagne
  • Manager of SCI Fleurus Immobilier
  • Chairman of SAS Dragon 8
  • Managing partner of SC Financière des Associés
  • Chairman of the Supervisory Board of SCA Chevrillon & Associés
  • Manager of EARL Ferme de Bissy
  • Managing partner of SC Valois
  • Co-manager of SC Aster
  • Managing partner of SCI du Chardonnet

 

Bryan GIRAUDO

Director

 

  • Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc
  • Director of Protagonist Therapeutics
  • Senior Managing Director at Leerink Partners

Antoine BAROUKY

Chief Operating Officer and Director

  • Chairman & CEO of MAAsiRNA
  • Chairman & CEO of AB Global Strategy
  • Venture Partner at Invus

 

Shefali AGARWAL

Director

 

  • Member of the Board of Directors of ITB Med (unlisted)
  • Member of the Board of Directors of Gritstone Bio (Nasdaq: GTRS)
  • Member of the Board of Directors of Fate Therapeutics (Nasdaq: FATE)

VALERIO THERAPEUTICS
Société anonyme à conseil d’administration au capital social de 21.610.998,20 euros
Siège social : 49 boulevard du Général Martial Valin, 75015 Paris 410 910 095 R.C.S. Paris

Contacts

VALERIO THERAPEUTICS

VALERIO THERAPEUTICS

BOURSE:ALVIO
Release Versions
English

Contacts

VALERIO THERAPEUTICS

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (“Valerio” or the “Company”), today announces that it has entered into a binding term-sheet with Abivax SA (“Abivax”), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement....

Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has signed a binding offer for the acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologi...

Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics (the "Company"), today announces the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders’ general meeting held on 16 June 2026 (the "General Meeting"). The General Meeting approved all reso...
Back to Newsroom